![]() Vijay Virkumar Vazirani honoured with the KnowDis Award for Excellence November 02, 2023 Sweet Truths: WHO Advises Against Non-Sugar Sweeteners for Better Health November 03, 2023ĪISATS Delivers 100 Automated Aircraft Exterior Cleanings for Vistara November 02, 2023 ![]() GEF India launches 10 Litre Multi-Use Jar of Freedom Refined Sunflower Oil November 03, 2023Ī New Hope for Sickle Cell Patients: Groundbreaking Gene Therapy Under FDA Review November 03, 2023 Uganda Airlines Selects Çelebi India as Its Preferred Ground Handling Services Partner in Mumbai, India November 03, 2023 Venus Remedies Limited Expands Global Reach with the Launch of Elores in Ecuador November 03, 2023 Transformative Partnership: Zydus and Guardant Health Join Forces for Cancer Testing in India and Nepal November 04, 2023 : A Positive Shift in Tamil Nadu's Healthcare November 06, 2023 Navigating Tomorrow: The Evolution of Healthcare Education through Simulation Models November 06, 2023īeyond the Clinic Walls: Office-Based Laryngology Training for Doctors in India November 06, 2023 #AgenaBioscience #LatestNewsonAgenaBioscience2ndDec #LatestPharmaNews2ndDec #Pandemic #FluSeason #TestingCapacity "Agena's respiratory molecular detection kits and MassARRAY Systems are ready for immediate deployment and we are equipped to provide reliable supply on a continuing basis." Tags : "Agena proactively sourced and secured materials, in order to provide uninterrupted product availability to our customers," explained Jason Halsey, Senior Vice President of Technology and Operations. With the panel's release, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or assay availability. "The MassARRAY SARS-CoV-2/Flu Panel design includes a dual target assay for SARS-CoV-2 in addition to sophisticated assays that cover all flu A and flu B strains, enabling reliable detection and differentiation of these respiratory viruses." "Multi-respiratory viral detection will be critical to differentiate influenza from SARS-CoV-2 infections," said Dr Darryl Irwin, Vice President of Scientific Affairs. "The MassARRAY SARS-CoV-2/Flu Panel helps meet these challenges by offering laboratories a high-throughput, low-cost solution to support the continued increase in demand." ![]() It is paramount that labs have access to testing that can accurately differentiate between SARS-CoV-2, influenza A, and influenza B viral RNA, without the need to reduce testing capacity or add resources," said Peter Dansky, CEO of Agena Bioscience. "This flu season, many expect the demands on laboratories to further escalate as the pandemic persists. With unprecedented sample volumes expected, this flu season poses critical testing challenges for laboratories, which must reliably and efficiently differentiate between SARS-CoV-2 and influenza RNA. ![]() The panel is available for research use only. Agena Bioscience, a global provider of low-cost and high-throughput molecular testing solutions, today announced the launch of the MassARRAY SARS-CoV-2/Flu Panel (RUO) for qualitative detection of SARS-CoV-2, influenza A, and influenza B viral RNA. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |